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Abstract
OBJECTIVE: To evaluate the value of a dedicated interpretation of the CT images in the differential
diagnosis of benign vs. malignant primary bone lesions with 18 fluorodeoxyglucose-positron emission
tomography/computed tomography (18F-FDG-PET/CT). MATERIALS AND METHODS: In 50
consecutive patients (21 women, 29 men, mean age 36.9, age range 11-72) with suspected primary bone
neoplasm conventional radiographs and 18F-FDG-PET/CT were performed. Differentiation of benign
and malignant lesions was separately performed on conventional radiographs, PET alone (PET), and
PET/CT with specific evaluation of the CT part. Histology served as the standard of reference in 46
cases, clinical, and imaging follow-up in four cases. RESULTS: According to the standard of reference,
conventional 17 lesions were benign and 33 malignant. Sensitivity, specificity, and accuracy in
assessment of malignancy was 85%, 65% and 78% for conventional radiographs, 85%, 35% and 68%
for PET alone and 91%, 77% and 86% for combined PET/CT. Median SUV(max) was 3.5 for benign
lesions (range 1.6-8.0) and 5.7 (range 0.8-41.7) for malignant lesions. In eight patients with bone lesions
with high FDG-uptake (SUV(max) >or= 2.5) dedicated CT interpretation led to the correct diagnosis of
a benign lesion (three fibrous dysplasias, two osteomyelitis, one aneurysmatic bone cyst, one fibrous
cortical defect, 1 phosphaturic mesenchymal tumor). In four patients with lesions with low FDG-uptake
(SUV(max) < 2.5) dedicated CT interpretation led to the correct diagnosis of a malignant lesion (three
chondrosarcomas and one leiomyosarcoma). Combined PET/CT was significantly more accurate in the
differentiation of benign and malignant lesions than PET alone (p = .039). There was no significant
difference between PET/CT and conventional radiographs (p = .625). CONCLUSION: Dedicated
interpretation of the CT part significantly improved the performance of FDG-PET/CT in differentiation
of benign and malignant primary bone lesions compared to PET alone. PET/CT more commonly
differentiated benign from malignant primary bone lesions compared with conventional radiographs, but
this difference was not significant.
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To evaluate the value of a dedicated interpretation of the CT images in the differential 
diagnosis of benign vs. malignant primary bone lesions with 18F-FDG-PET/CT. 
Methods 
In 50 consecutive patients (21 female, 29 male, mean age 36.9, age range 11 – 72) 
with suspected primary bone neoplasm conventional radiographs and 18F-FDG-
PET/CT were performed. Differentiation of benign and malignant lesions was 
separately performed on conventional radiographs, PET alone (PET) and PET/CT 
with specific evaluation of the CT part. Histology served as the standard of reference 
in 46 cases, clinical and imaging follow-up in four cases. 
Results 
According to the standard of reference conventional 17 lesions were benign and 33 
malignant. Sensitivity, specificity and accuracy in assessment of malignancy was 
85%, 65% and 78% for conventional radiographs, 85%, 35% and 68% for PET alone 
and 91%, 77% and 86% for combined PET/CT. Median SUV max. was 3.5 for benign 
lesions (range 1.6 – 8.0) and 5.7 (range 0.8 – 41.7) for malignant lesions.  
In eight patients with bone lesions with high FDG-uptake (SUV max.≥2.5) dedicated 
CT interpretation led to the correct diagnosis of a benign lesion (3 fibrous dysplasias, 
2 osteomyelitis, 1 aneurysmatic bone cyst 1 fibrous cortical defect, 1 phosphaturic 
mesenchymal tumor). In four patients with lesions with low FDG-uptake (SUV max. 
<2.5) dedicated CT interpretation led to the correct diagnosis of a malignant lesion 
(three chondrosarcomas and one leiomyosarcoma). Combined PET/CT was 
significantly more accurate in the differentiation of benign and malignant lesions than 
PET alone (p=.039). There was no significant difference between PET/CT and 
conventional radiographs (p=.625).  
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Conclusion 
Dedicated interpretation of the CT part significantly improved the performance of 
FDG-PET/CT in differentiation of benign and malignant primary bone lesions 
compared to PET alone. PET/CT more commonly differentiated benign from 
malignant primary bone lesions compared with conventional radiographs but this 
difference was not significant. 
 
Introduction 
Currently, the workup of primary bone neoplasms includes conventional radiographs 
and typically magnetic resonance imaging (MRI) for local staging as well as bone 
scintigraphy (BS) and computed tomography (CT) for general staging. If malignancy 
is suspected, bone biopsy has to be performed. FDG-PET and FDG-PET/CT are 
increasingly used for the differentiation of malignant and benign tumors in many 
organ systems (1-5). However, the role of PET/(CT) in the evaluation of bone tumors 
is not well defined, yet (6, 7). Preliminary results showed that PET/(CT) may play an 
important role in biopsy guidance (8), grading (9, 10), staging (11) and therapy 
response assessment (12, 13). Differentiation between benign and malignant primary 
bone lesions is crucial and has an important impact on therapy. FDG uptake 
measured by maximum conventionalized uptake value (SUV max) is not reliable 
enough because of a considerable overlap between FDG uptake of benign and 
malignant bone lesions. It is known that especially histiocytic or giant cell containing 
benign lesions can have FDG uptake >2.5 SUV max (14). Conventional PET 
scanners are increasingly replaced by combined PET/CT. The CT part can be used 
for attenuation correction and anatomic correlation of FDG-positive lesions. In 
addition, a specific interpretation of the CT part of the PET/CT study may improve 
diagnostic performance (15). The aim of this study was evaluate the additional value 
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of such an interpretation in the differential diagnosis of benign vs. malignant primary 
bone lesions. 
Materials and Methods: 
Patients 
50 consecutive patients (21 female, 29 male, mean age 36.9, age range 11 – 72) 
were prospectively included in this study. In all patients a primary bone tumor was 
suspected because of clinical symptoms (pain, fracture; n=42) and/or imaging 
findings (n=8). In all patients conventional radiographs and an 18F-FDG-PET/CT 
examination were performed. The time interval between the radiographs and PET/CT 
was <14 days in all cases. There was no therapeutic intervention between 
conventional and PET/CT imaging. 
The study was conducted in accordance with the guidelines established by the local 
ethics committee. 
PET/CT imaging protocol 
All data were acquired on a combined PET/CT in-line system (Discovery LS or 
Discovery STE, GE Healthcare, Milwaukee, WI, USA).  
Patients fasted for at least 4 hours prior to scanning, which started approximately 60 
minutes (median 58 min.; range 52 – 77 min.) after the injection of 350 - 400 MBq of 
18F-FDG. All patients were tested for a normal glucose level before scanning. 
Patients with elevated glucose levels were rescheduled and scanned with normal 
glucose levels. No intravenous contrast agent was given. Initially, the CT scan was 
acquired starting from the level of the head using the following parameters: 40 mAs, 
140 kV, 0.5 sec/tube rotation, slice thickness 4.25 mm, scan length 867 mm, data-
acquisition time 22.5 seconds. Breathhold CT in non-forced expiration position was 
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performed. In the patients with primary tumors in the lower extremities, scanning of 
the lower legs was added. 
Immediately following CT acquisition, a PET emission scan was acquired with an 
acquisition time of 3 minutes per bed position with a one-slice overlap in 2D mode 
(matrix 128 x 128). The eight to nine bed positions starting from the head to the 
knees resulted in an acquisition time of approximately 24-27 minutes. CT data were 
used for the attenuation correction and the images were reconstructed using a 
conventional iterative algorithm (OSEM). The acquired images were viewed with a 
software providing multiplanar reformatted images of PET alone, CT alone and fused 
PET/CT with linked cursors (Advantage Windows workstation, GE Healthcare, 
Milwaukee, WI, USA). PET/CT imaging was performed according to the published 
“procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0”(16). 
Standard of Reference 
Histology, obtained by image-guided (ultrasound or CT) or open biopsy or tumor 
resection served as the standard of reference in 46 cases. The histopathological 
examination were performed by a board certified pathologist (B.B). The tumor 
diagnoses were done according to the criteria of the World Health Organization and if 
indicateded were confirmed by the appropriate molecular methods (fluorescence in 
situ hybridization (FISH) and/or polymerase chain reaction (PCR)). Imaging and 
clinical follow-up for at least 12 months (mean 24 months, range 12 – 36) was used 
as the standard of reference in the remaining four cases. 
Interpretation of conventional radiographs 
Conventional radiographs were analyzed by a radiologist (J.H.). The reader was 
blinded to the results of other imaging modalities and to the clinical history but aware 
about the suspicion of a bone tumor. Differentiation of benign and malignant lesions 
were based on the established criterias described by Lodwick and several other 
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authors (17-19). Signs of benignity were for example: well defined lesions, rim 
sclerosis, ground glass appearance. Signs of malignancy were for example ill defined 
lesions, cortical destruction, malignant periosteal reactions. 
PET/CT interpretation and measurement of SUV max. 
Semiquantitative analysis of FDG uptake was performed by measuring the SUV max. 
In our institution, SUV is corrected for lean body mass. A personal scale (Tanita, 
model 2001; Tanita, Tokyo, Japan) with an integrated foot-to-foot bioelectric 
impedance analyser was used to determine the lean body mass (LBM) of the 
patients. The manufacturer supplied a model including gender, weight, height, and a 
measured impedance value for determination of the percentage of body fat and for 
calculation of LBM. By using attenuation-corrected PET data, SUV max. were 
calculated with the following equation based on a freehand region of interest 
including the entire lesion on the fused PET/CT image: SUV max(lbm) = (LBM – 
CFDG)/Dose where LBM is measured in grams, CFDG is the concentration of 18F-FDG 
in Becquerels per milliliter, and Dose is the injected dose measured in Becquerels. 
Physiological 18F-FDG uptake and uptake caused by benign abnormalities for 
instance in muscles, brown fat or pulmonary infiltrates were excluded from the 
analysis. 
For the evaluation with PET alone a SUV max. cutoff of 2.5 was used for the 
differentiation of low FDG-uptake (<2.5 max.) versus high FDG-uptake (≥2.5 SUV 
max.). Lesions with low FDG uptake were interpreted as benign and lesions with high 
FDG uptake as malignant The SUVmax. measurements were performed by a nuclear 
physician (K.D.M.S.), again blinded to the results of the other imaging modalities and 
the clinical history but aware about the suspicion of a bone tumor. For the combined 
PET/CT evaluation the CT part of the PET/CT study was separately analyzed by a 
reader with double board certification as a radiologist and a nuclear medicine 
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physician (K.S.). He was also blinded to the results of the other imaging modalities 
and the clinical history. He was only aware that a bone tumor was suspected. (20-
22). Signs of benignity were for example: well defined lesions, rim sclerosis, ground 
glass appearance. Signs of malignancy were for example ill defined lesions, cortical 
destruction, malignant periosteal reactions. Bone and soft tissue window settings 
were used for the evaluation. In lesions with low uptake but aggressive CT 
appearance, including aggressive periosteal reactions and cortical destruction, the 
final PET/CT interpretation was that of malignant lesion. In cases of PET-positive 
lesions, indicating malignancy  with benign CT patterns such as a well-defined 
osteolysis with rim sclerosis the final interpretation was that of a benign lesion. 
Statistical Analysis 
Data were analysed using SPSS 15 for Windows (SPSS Inc.). Statistical significance 
was assessed with the sign test. P<.05 was considered to indicate a significant 
difference.  
Results 
Seventeen lesions were benign and 33 malignant. In the benign group there were 
seven benign bone tumors (Fig.1/2,3/4), three fibrous dysplasias (Fig.5/6), two 
osteomyelitis, one insertion tendinopathy, one stress fracture, one postoperative 
defect, one fibrous cortical defect and one bone infarction. Of the 33 malignant 
lesions there were 18 sarcomas (Fig.7/8), six lymphomas, three metastases, one 
melanoma, one chordoma, one hemangioendothelioma, one eosinophilic 
granumloma, one malignant peripheral nerve sheath tumor and one neuroendocrine 
tumor. Patient characteristics are summarized in table 1. Median SUV max. of benign 
lesions was 3.5 (range 1.6 – 8.0) and 5.7 (range 0.8 – 41.7) for malignant lesions 
(Table 2). Sensitivity, specificity, accuracy, PPV and NPV regarding the diagnosis of 
a malignant lesions was 85%, 65%, 78%, 82% and 67% for CI, 85%, 35%, 68%, 72% 
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and 55% for PET alone and 91%, 77%, 86%, 88% and 81% for combined PET/CT 
(Table 3). 
In eight patients with a SUV max. >2.5, the dedicated CT interpretation led to the 
correct diagnosis of a benign lesion (3 fibrous dysplasias, 2 osteomyelitis, 1 
aneurysmal bone cyst, 1 fibrous cortical defect, 1 phosphaturic mesenchymal tumor). 
In four patients with a SUV max<2.5 CT interpretation led to the correct diagnosis of 
a malignant lesion (three chondrosarcoma, one leiomyosarcoma). Combined PET/CT 
interpretation was significantly more accurate compared to PET alone (p=.039). The 
diagnostic performance of PET/CT was not significantly different from conventional 
radiographs (p=.63). Furthermore, no statistically significant difference was found 
between PET alone and conventional radiographs (p= .18). 
 
Discussion 
Although malignant bone lesions have generally higher FDG uptake than benign 
bone tumors, there is a considerable overlap regarding the amount of FDG uptake. 
Our results confirm the findings of previously published studies that many benign 
lesions can have moderate to high FDG-uptake (14, 23). This fact can lead to 
misinterpretation because incidentally detected benign FDG-positive bone lesions 
may mimic metastases if FDG-PET/CT is performed for staging of extra-skeletal 
malignancies (23, 24). Fibrous dysplasia is a good example where separate 
interpretation of CT images with the pathognomonic “ground glass” pattern and 
absence of bone destruction overrules the positive PET result and leads to the 
correct diagnosis of a “no-touch” benign lesion (25). We found SUV max. values >2.5 
(range 2.9 – 8.0) in all four patients with fibrous dysplasia. Aoki et al. published 6 
cases with fibrous dysplasia, of which only two presented with a SUV max. >2.5 (14).  
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Low-grade chondrosarcomas are good examples in which interpretation of the CT 
part with the typical calcifications overrules a negative PET result and leads to the 
correct diagnosis of a malignant lesion. Three of our four condrosarcomas had SUV 
max. values <2.5 which confirms the results of other authors that especially low-
grade chondrosarcomas can be almost FDG-negative (26). 
FDG uptake is not specific for the diagnosis of a malignant neoplasm. Traumatic, 
inflammatory and infectious lesions like osteomyelitis can show significant FDG 
uptake as shown in experimental and clinical studies (27, 28). We observed SUV 
max. of 5.2 and 6.9 in both of our patients with biopsy-proven osteomyelitis.  
F-18 FDG PET/CT has been employed for differentiation between malignant and 
benign fractures based on the SUV max. and based on medullary uptake, which is 
characteristic for malignant fractures (29, 30). Fractures in two of our patients were 
caused by benign lesions, one was PET positive (SUV max. 3.9 in a patient with 
fibrous dysplasia) and one PET negative (SUV max. 1.6 in a patient with a stress 
fracture).  
Our results underline that the CT part of the PET/CT study can add important 
information. Those evaluating PET/CT studies should be familiar with both the 
metabolic and morphologic features of bone tumors and tumor-like lesions.  
Similarly to previously published studies our data indicate the difficulty to define a 
reliable cutoff value for the differentiation between benign and malignant lesions. 
Beside the previously described cutoff value of SUV max. = 2.5, also values of 2.0 or 
3.0 do not provide sufficient accuracy (14, 31, 32). Since the SUV is a 
semiquantitative measurement there are various calculation variants and 
reproducibility suffers from influences such as blood glucose level, uptake time and 
several others. Therefore, the use of additional criteria for diagnosing bone 
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neoplasms is important (33). Nevertheless, Dehdashti et al. have demonstrated that 
SUV measurements were more effective than subjective interpretation of FDG uptake 
in bone lesions (34). We believe that a combined interpretation of metabolic 
information and morphologic information, both provided by a PET/CT examination 
should be implemented. 
Conventional radiographs remain the first imaging modality in the evaluation of 
suspected bone neoplasms. A final diagnosis can often be made based on 
radiographs, obviating additional imaging and biopsy. This is the case for fibrous 
dysplasia, Paget`s disease and nonossifying fibroma. In equivocal cases and in 
aggressive tumors such as osteosarcoma MR imaging is typically employed as the 
second imaging tool for grading and staging (35). The importance of bone 
scintigraphy for the evaluation of bone tumors has decreased over the last years. 
However, this method still is valuable in staging of osteosarcoma. The accuracy of a 
bone scan can be increased by using SPECT and SPECT/CT (36, 37). 
Because combined FDG-PET/CT did not improve differentiation of bone lesions 
compared to conventional radiographs it can not be recommended for this indication. 
Another problem in clinical routine in most countries is the fact that PET/CT is only 
reimbursed for staging of confirmed malignant tumors but not for assessment of 
malignancy in equivocal cases. PET/CT has a potential role for the detection of 
transformation of a benign into a malignant bone tumor and of development into 
more aggressive patterns as observed in malignant lymphoma (38). We observed no 
proven transformation in our patients and studies with high numbers of patients with 
transformation are missing because such malignant transformations are infrequent 
(39). 
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Our study has limitations. For the CT evaluation only a low-dose CT part of the 
combined PET/CT study was available. Another approach would be to perform a 
thin-slice conventional “high-dose” CT centered on the primary bone lesions. This 
better CT quality may improve the performance of the combined PET/CT. This study 
is intentionally limited to the assessment of the dignitiy of the primary lesion but does 
not assess additional information provided by the PET/CT such as grading and 
staging of a proven malignant tumor, or detection of multifocality, second primaries or 
metastases. These aspects have been investigated before in other publications (7, 
36, 40, 41). Delayed images might help in the differentiation between benign and 
malignant bone lesions like observed in soft tissue sarcomas (42). Because of our 
busy schedule with approx. 20 PET/CT scans per day we were not able to evaluate 
the additional value of delayed images. 
In conclusion, dedicated interpretation of the CT part significantly improved the 
performance of FDG-PET/CT in differentiation of benign vs. malignant primary bone 
lesions compared to PET alone. PET/CT more commonly differentiated benign from 
malignant primary bone lesions compared with conventional radiographs but this 





Characteristics of 50 patients with benign and malignant bone lesions. 
pat no. SUV max. final diagnosis 
1 5.2 Brodie abscess 
2 2.5 lymphoma 
3 11.3 osteosarcoma 
4 7.4 leiomyosarcoma 
5 3.6 neuroendocrine tumor 
6 5.1 Ewing sarcoma 
7 6.2 lymphoma 
8 1.6 stress fracture 
9 2.9 fibrous dysplasia 
10 6.9 osteomyelitis 
11 3.5 phosphaturic mesenchymal tumor 
12 1.4 Chondrosarcoma 
13 8.0 fibrous dysplasia 
14 3.9 fibrous dysplasia with pathologic fracture 
15 9.0 Leiomyosarcoma 
16 4.6 fibrous cortical defect 
17 9.0 Lymphoma 
18 8.8 malignant peripheral nerve sheaeth tumor 
19 0.8 Eosinophilic granuloma 
20 2.0 osteochondroma 
21 3.0 hemangioendothelioma 
22 4.0 chondroblastoma 
23 41.7 lymphoma 
24 14.9 osteosarcoma 
25 5.9 lymphoma 
26 3.7 aneurysmatic bone cyst 
27 3.1 chondrosarcoma 
28 1.4 leiomyosarcoma 
29 4.7 clear cell renal carcinoma metastasis 
30 7.7 fibrous dysplasia 
31 2.2 bone infarction 
32 2.1 insertion tendinopathy 
33 2.2 haemangioma 
34 3.5 enchondroma 
35 1.3 postoperative defect 
36 2.2 chondrosarcoma 
37 8.7 osteosarcoma 
38 5.3 osteosarcoma 
39 5.7 osteosarcoma 
40 11.3 lymphoma 
41 3.5 Ewing sarcoma 
42 10.9 NSCLC metastasis 
43 3.0 chordoma 
44 10.7 NSCLC metastasis 
45 12.0 Melanoma 
46 5.0 Ewing sarcoma 
47 7.8 osteosarcoma 
48 5.4 Ewing sarcoma 
49 2.3 chondrosarcoma 
50 13.2 osteosarcoma 
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NSCLC=non small cell lung cancer, SUV=conventionalized uptake value 
Table 2 




Performance of conventional x-rays (CI), PET alone (PET) and combined PET/CT 
(PET/CT) in the differentiation of benign vs. malignant primary bone lesions in 50 
patients. 
 CI PET PET/CT 
sensitivity 85% 85% 91% 
specificity 65% 35% 77% 
accuracy 78% 68% 86% 
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PPV 82% 72% 88% 
NPV 67% 55% 81% 




Fig. 1              Fig.2 
Conventional x-ray images of the right knee of a 15 years old boy showing an osteolysis (arrows) in the epiphysis of the right proximal 
tibia. Moderate FDG-uptake (SUV max. 4.0) of the lesion on PET images (2a, MIP). Axial PET (2b) and fused PET/CT (2d) images 
demonstrating that the tumor takes up FDG in the periphery with a FDG-negative centre. CT(2c) shows a well-defined excentric 
osteolysis without clear sclerotic rim. No calcifications are seen inside the lesion. So also in CT this lesion was difficult to assess 





Fig. 3     Fig.4 
 
Conventional x-ray images of the left tigh in a 21 years old male patient with a calcified lesion in the upper third of the diaphysis of the 
left tibia (arrows). PET (MIP 4a; axial PET 4b; fused PET/CT images 4d) with increased FDG-uptake (SUV max.3.5) of the lesion 
(arrows) indicating malignancy. CT (4c) images demonstrating calcifications (arrowheads) without cortical destructions typical for an 





Fig. 5       Fig.6 
Conventional x-ray images (Fig.5) of a 33 years old female patient with an inhomogeneous ground-glass like lesion (arrows) in the 
left tibia. FDG-PET (MIP 6 a; axial PET 6b, fused PET/CT images 6d) showing intense FDG-uptake (SUV max.7.7) of the lesion 
indicating malignancy. CT (6c) demonstrating well defined ground glass lesions without cortical destruction typical for fibrous 




50 year old female patient with a calcified lesion in the bone marrow of the left 
proximal humerus. PET (Fig. 7 a,b,d) images demonstrating low FDG-uptake (SUV 
max. 2.3) in the lesion (arrows) indicating benignity. CT (arrow, Fig. 7c) shows 
calcifications inside the lesion with cortical destructions (arrow,d) suspicious for 
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